title: Functional significance of vitamin D receptor FokI polymorphism in human breast cancer cells.
abstract: BACKGROUND
  The FokI vitamin D receptor (VDR) polymorphism results in different translation initiation sites on VDR. In the VDRff variant, initiation of translation occurs at the first ATG site, giving rise to a full length VDR protein of 427 amino acids. Conversely, in the VDRFF variant, translation begins at the second ATG site, resulting in a truncated protein with three less amino acids. Epidemiological studies have paradoxically implicated this polymorphism with increased breast cancer risk. 1α,25 (OH)(2)D(3), the active metabolite of vitamin D, is known to inhibit cell proliferation, induce apoptosis and potentiate differentiation in human breast cancer cells. It is well documented that 1α,25 (OH)(2)D(3) downregulates estrogen receptor α expression and inhibits estrogen mediated signaling in these cells. The functional significance of the VDR FokI polymorphism in vitamin D action is undefined.
  
  
  RESULTS
  To elucidate the functional role of FokI polymorphism in breast cancer, MCF-7-Vector, MCF-7-VDRff and MCF-7-VDRFF stable cell lines were established from parental MCF-7 cells as single-cell clones. In response to 1α,25 (OH)(2)D(3) treatments, cell growth was inhibited by 60% in VDRFF cells compared to 28% in VDRff cells. The induction of the vitamin D target gene CYP24A1 mRNA was 1.8 fold higher in VDRFF cells than in VDRff cells. Estrogen receptor-α protein expression was downregulated by 62% in VDRFF cells compared to 25% in VDRff cells. VDR protein stability was greater in MCF-7-VDRFF cells in the presence of cycloheximide. PCR array analyses of VDRff and VDRFF cells revealed increased basal expression levels of pro-inflammatory genes Cyclooxygenase-2, Interleukin-8 and Chemokine (C-C Motif) Ligand 2 in MCF-7-VDRff cells by 14, 52.7 and 5 fold, respectively.
  
  
  CONCLUSIONS
  These results suggest that a VDRff genotype may play a role in amplifying aggressive breast cancer, paving the way for understanding why some breast cancer cells respond inefficiently to vitamin D treatment.
authors.affiliation: Division of Cancer Biology, IIT Research Institute, Illinois Institute of Technology, Chicago, Illinois, United States of America.
authors.forename: Fatouma
authors.initials: F
authors.lastname: Alimirah
authors.forename: Xinjian
authors.initials: X
authors.lastname: Peng
authors.forename: Genoveva
authors.initials: G
authors.lastname: Murillo
authors.forename: Rajendra G
authors.initials: RG
authors.lastname: Mehta
mesh_terms: D001943:Breast Neoplasms / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D018387:Codon, Initiator / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D007249:Inflammation / Q000235:genetics; D011110:Polymorphism, Genetic; D018167:Receptors, Calcitriol / Q000235:genetics*; D013250:Steroid Hydroxylases / Q000235:genetics; D014807:Vitamin D / Q000494:pharmacology / Q000627:therapeutic use; D065668:Vitamin D3 24-Hydroxylase
chemical_list: D018387:Codon, Initiator; D018167:Receptors, Calcitriol; D014807:Vitamin D; D013250:Steroid Hydroxylases; C585549:CYP24A1 protein, human; D065668:Vitamin D3 24-Hydroxylase